Sun Y, Gan W, Lei M, Jiang W, Cheng M, He J, et al
If more blood sugar control is required, the dosage can be raised to 10 mg once daily
Sampedros team ( 4.4 Long-term safety and off-target effects Emerging reports link GLP-1RAs to rare ocular adverse events, including NAION ( 5 Conclusion In conclusion, the expanding body of evidence supports that GLP-1RAs offer a multifaceted approach to ocular therapeutics by targeting key molecular pathways involved in retinal neuroprotection, mitochondrial regulation, inflammation, vascular remodeling, and angiogenesis
Direct comparison: For research focused on body composition endpoints, retatrutide has become the most-cited compound in head-to-head studies
Industry publications framed the event in stark terms, with one headline reading, Skye Bioscience stock plummets after failed weight loss drug trial. SEC Filings & Risk Factors Skye's 2024 10-K (March 20, 2025) disclosed standard biotech perils: "Clinical trials may fail to demonstrate safety and efficacy," with specifics on nimacimab's Phase 2 uncertainties, including "potential for suboptimal dosing" and "failure to meet endpoints." Yet plaintiffs argue these were boilerplate, omitting known gaps in preclinical-to-clinical translation
Anti-inflammatory effects that may support recovery 4